DEDIFFERENTIATION OF NON-HEMATOPOIETIC TISSUE BY GENETIC MANIPULATION AND ITS ACQUISITION OF PLASTICITY AND HEMATOPOIETIC TRANSDIFFERENTIATION

通过基因操作实现非造血组织的去分化及其可塑性和造血转分化的获得

基本信息

  • 批准号:
    16390281
  • 负责人:
  • 金额:
    $ 7.68万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2004
  • 资助国家:
    日本
  • 起止时间:
    2004 至 2005
  • 项目状态:
    已结题

项目摘要

We explored the possibility that genetic manipulation may enhance the efficiency of transdifferentiation of non-hematopoietic tissue. Transient overexpression of Msx1 in muscles was reported to generate abundant mononuclear cells (MNCs) capable of differentiation into myotubes, chondrocytes, adipocytes and osteocytes. Since virtually all of AAV vector-mediated transgenes exist as a non-integrated form, they gradually disappear as the host cells divide. We took advantage of this feature of AAV vectors ; i.e. muscle-derived MNCs lose Msx1 transgenes through multiple cell divisions after dedifferentiation. We postulated that a proper differentiation cue might redirect muscle-derived undifferentiated MNCs into a hematopoietic lineage. AAV5 vector expressing Msx1 (AAV-msx1) was injected into tibialis anterior muscles of C57BL/6 mice. Flow cytometric analysis revealed that MNCs from AAV-msx1-treated muscles contained a considerable number of cells expressing hematopoietic stem cell markers. To evaluate hematopoietic activity, MNCs were cultured in methylcellulose medium. After AAV-msx1 injection, colony-forming cells in the muscles were gradually increased, reaching a peak at 3 wk. In vivo hematopoietic reconstitution activity was also evaluated by transplanting MNCs from AAV-msx1-treated muscles of Ly5.2 mice to irradiated congenic mice. Efficient engraftment of Ly5.2 cells was observed, and these transplants showed a very high chimerism of Ly 5.2. Furthermore, in the secondary bone marrow transplantation from the former mouse to a Ly5.1/5.2 heterozygous recipient, the donor cell chimerism was even higher. These results suggest that enforced Msx1 expression can reprogram muscle cells into multipotential cells capable of differentiation into a hematopoietic lineage as well. This novel technology would be applied to the treatment of acquired bone marrow failure using genetically-normal hematopoietic stem cells derived from patient muscles.
我们探讨了基因操作可能提高非造血组织转分化效率的可能性。据报道,肌肉中Msx1的瞬时过表达产生大量能够分化成肌管、软骨细胞、脂肪细胞和骨细胞的单核细胞(MNCs)。由于几乎所有的AAV载体介导的转基因都以非整合形式存在,它们随着宿主细胞分裂而逐渐消失。我们利用了腺相关病毒载体的这一特征;即肌肉来源的单核细胞在去分化后通过多次细胞分裂失去Msx 1转基因。我们假设适当的分化线索可能会将肌肉来源的未分化MNCs重新定向为造血谱系。将表达Msx1的AAV5载体(AAV-msx1)注射到C57BL/6小鼠的胫骨前肌中。流式细胞术分析显示,从AAV-msx1处理的肌肉的MNC含有相当数量的细胞表达造血干细胞标志物。为了评价造血活性,将MNC在甲基纤维素培养基中培养。注射AAV-msx1后,肌肉中的集落形成细胞逐渐增多,在3wk时达到高峰。还通过将来自AAV-msx 1处理的Ly5.2小鼠肌肉的MNC移植到辐射的同类小鼠来评价体内造血重建活性。观察到Ly5.2细胞的有效植入,并且这些移植物显示出非常高的Ly5.2嵌合性。此外,在从前小鼠到Ly5.1/5.2杂合受体的二次骨髓移植中,供体细胞嵌合性甚至更高。这些结果表明,加强Msx1表达可以重编程肌肉细胞成多能细胞能够分化成造血谱系以及。这项新技术将应用于使用来自患者肌肉的遗传正常的造血干细胞治疗获得性骨髓衰竭。

项目成果

期刊论文数量(83)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hematopoietic microchimerism in sheep after in utero transplantation of cultured cynomolgus embryonic stem cells.
培养的食蟹猴胚胎干细胞宫内移植后绵羊的造血微嵌合。
rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse
Large-scale production of recombinant viruses by use of a large culture vessel with active gassing.
使用具有主动通气功能的大型培养容器大规模生产重组病毒。
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Okada;T.;Nomoto;T.;Yoshioka;T.;Nonaka-Sarukawa;M.;Ito;T.;Ogura;T.;Iwata-Okada;M.;Uchibori;R.;Shimazaki;K.;Mizukami;H.;Kume;A.;Ozawa;K.
  • 通讯作者:
    K.
Separate control of Rep and Cap expression utilizing mutant and wild-type loxP sequences and improved packaging system for adeno-associated virus vector production.
利用突变型和野生型 loxP 序列以及改进的腺相关病毒载体生产包装系统单独控制 Rep 和 Cap 表达。
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mizukami H;et al.
  • 通讯作者:
    et al.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OZAWA Keiya其他文献

OZAWA Keiya的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OZAWA Keiya', 18)}}的其他基金

Development of a site-specific gene insertion technology for regenerative medicine:Basic study using developmental engineering
再生医学定点基因插入技术的开发:利用发育工程的基础研究
  • 批准号:
    23659493
  • 财政年份:
    2011
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Development of gene therapy using bone-marrow-derived mesenchymal stem cells
使用骨髓间充质干细胞进行基因治疗的开发
  • 批准号:
    21390296
  • 财政年份:
    2009
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of gene therapy for malignant lymphoma using mesenchymal stem cells with tumor-accumulating capacity
利用具有肿瘤蓄积能力的间充质干细胞开发恶性淋巴瘤基因治疗
  • 批准号:
    19390267
  • 财政年份:
    2007
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of AAV (adeno-associated virus) vectors and their application to cancer therapy
AAV(腺相关病毒)载体的开发及其在癌症治疗中的应用
  • 批准号:
    17016067
  • 财政年份:
    2005
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
Development of the gene therapy technologies using adeno-associated virus (AAV)
使用腺相关病毒(AAV)的基因治疗技术的开发
  • 批准号:
    12470203
  • 财政年份:
    2000
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development and application of the technologies for manipulationg hematopoietic stem cells using cell-regulatory genes
细胞调控基因操控造血干细胞技术的开发与应用
  • 批准号:
    11557075
  • 财政年份:
    1999
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
Development of the method for chromosomal site-specific integration of transgenes using AAV and its application to hematopoietic cells
AAV转基因染色体位点特异性整合方法的开发及其在造血细胞中的应用
  • 批准号:
    10470213
  • 财政年份:
    1998
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of a novel regulatory gene for in vivo & in vitro expansion of transduced hematopoietic stem cellss
开发一种新型体内调节基因
  • 批准号:
    09557087
  • 财政年份:
    1997
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of a novel gene therapy technology for site-specific integration of large-sized genes
开发用于大尺寸基因位点特异性整合的新型基因治疗技术
  • 批准号:
    08457280
  • 财政年份:
    1996
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular study of hematopoiesis-supporting ability of C3H10T1/2 mouse embryo fibroblasts
C3H10T1/2小鼠胚胎成纤维细胞造血支持能力的分子研究
  • 批准号:
    06454345
  • 财政年份:
    1994
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)

相似海外基金

Enhance myogenic transdifferentiation efficiency using engineering approaches
利用工程方法提高生肌转分化效率
  • 批准号:
    10647491
  • 财政年份:
    2023
  • 资助金额:
    $ 7.68万
  • 项目类别:
Metabolism and Epigenetic Regulation are Couples in Transdifferentiation and Vascular Regeneration
代谢和表观遗传调控是转分化和血管再生的结合体
  • 批准号:
    10905167
  • 财政年份:
    2023
  • 资助金额:
    $ 7.68万
  • 项目类别:
Elucidation of the molecular mechanism of transdifferentiation from chondrocytes to osteoblasts by Runx2
Runx2阐明软骨细胞向成骨细胞转分化的分子机制
  • 批准号:
    23K09121
  • 财政年份:
    2023
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Biphasic Regulation of Endothelial Transdifferentiation by Alcohol and Its Impact on Vascular Disease
酒精对内皮转分化的双相调节及其对血管疾病的影响
  • 批准号:
    10771448
  • 财政年份:
    2023
  • 资助金额:
    $ 7.68万
  • 项目类别:
Inhibiting Macrophage-to-Fibroblast Transdifferentiation in the Tumor Microenvironment of Gastrointestinal Cancers.
抑制胃肠道癌肿瘤微环境中的巨噬细胞向成纤维细胞转分化。
  • 批准号:
    23K19512
  • 财政年份:
    2023
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer
循环肿瘤细胞的微流体分离和分子分析用于前列腺癌神经内分泌转分化的研究
  • 批准号:
    10399782
  • 财政年份:
    2022
  • 资助金额:
    $ 7.68万
  • 项目类别:
Microfluidic cell squeezing platform for the transdifferentiation of somatic cells for efficient generation of a cell replacement therapy for Parkinsons Disease
用于体细胞转分化的微流控细胞挤压平台,可有效生成帕金森病的细胞替代疗法
  • 批准号:
    10483308
  • 财政年份:
    2022
  • 资助金额:
    $ 7.68万
  • 项目类别:
Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer
循环肿瘤细胞的微流体分离和分子分析用于前列腺癌神经内分泌转分化的研究
  • 批准号:
    10597026
  • 财政年份:
    2022
  • 资助金额:
    $ 7.68万
  • 项目类别:
Mechanisms underlying transdifferentiation of Kupffer's vesicle epithelial cells
库普弗囊泡上皮细胞转分化的机制
  • 批准号:
    22K20625
  • 财政年份:
    2022
  • 资助金额:
    $ 7.68万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Harnessing endothelial cell transdifferentiation for cardiovascular therapy
利用内皮细胞转分化进行心血管治疗
  • 批准号:
    10513527
  • 财政年份:
    2022
  • 资助金额:
    $ 7.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了